Evaluation of in vitro toxicity of peptide (N-acetyl-Leu-Gly-Leu-COOH)-substituted-β-cyclodextrin derivative, a novel drug carrier, in PC-12 cells
© Sadeghnia et al.; licensee BioMed Central Ltd. 2013
Received: 21 July 2013
Accepted: 2 September 2013
Published: 20 December 2013
Cyclodextrins (CDs) have been shown to improve physicochemical and biopharmaceutical properties of drugs when low solubility and low safety limit their use in the pharmaceutical field. Recently, a new amphiphilic peptide-substituted-β-CD, hepta-(N-acetyl-Leu-Gly-Leu)-β-CD (hepta-(N-acetyl-LGL)-β-CD), is developed which exhibited good solubility, strong inclusion ability and an appropriate average molecular weight. However, there is limited information available about its toxic effects. This study was designed to evaluate cytotoxic effects of the hepta-(N-acetyl-LGL)-β-CD (50, 200, 400, and 800 μg/ml) on rat pheochromocytoma PC-12 cells.
A significant reduction of cell viability with IC50 values of 1115.0 μg/ml, 762.4 μg/ml, and 464.9 μg/ml at 6, 12, and 24 h post-treatment, respectively, as well as increased lipid peroxide levels and DNA damage were observed.
In conclusion, hepta-(N-acetyl-Leu-Gly-Leu)-β-CD exhibit significant toxic properties at high concentrations, probably through induction of oxidative stress and genotoxicity.
Toxic potential, lack of efficacy, and especially low aqueous solubility, that lead to insufficient therapeutic concentration in physiological fluids, are main causes of drug delivery failure for approximately 40% of current and 90% of new drugs in the market according to biopharmaceutical classification system . In order to enhance aqueous solubility and membrane penetration of drugs, numerous methods including prodrugs, physical methods, and water-soluble nanocarrier systems such as liposomes, microemulsions, and polymeric nanoparticles have been provided [1, 2]. One of the beneficial techniques to improve the water solubility, bioavailability, and stability of drug formulations is the use of cyclodextrins (CDs) and chemically modified ones [3–6]. CDs are hydrophilic or relatively lipophilic oligomers that are produced by enzymatic degradation of starch. There are three major CDs: α-CD, β-CD, and γ-CD, which are composed of 6, 7 or 8 α -(1,4)-linked glucopyranose glucose residues, respectively, arranged in a cone-shaped, formed a hydrophilic outer surface and a somewhat lipophilic cavity [2, 7]. Because of their use as an excipient in pharmaceuticals, many studies have evaluated the safety of natural CDs and their derivatives in several in vitro and animal models [8, 9]. Genotoxicity test of CDs indicated that none of them are genotoxic and mutagenic. However, exocrine acinar cell neoplasia was observed in some studies . The hemolytic effect, one of the main disadvantages of CDs, also was evaluated in different studies and correlated with their effect to solubilize membrane cholesterol [10–12]. Recently, new amphiphilic β-CDs were designed by substitution of peptide chains on to the primary hydroxyl groups through ester bond formation between the carboxyl group of N-acetylated residues and C-6 of β-CD . In the present study, we investigated the toxicity of hepta-(N-acetyl-Leu-Gly-Leu)-β-CD (one of the peptide-substituted-β-CD) designed by Seyedi et al.  in PC-12 cells. Furthermore, lipid peroxidation and possible DNA damage were also evaluated.
Hepta-(N-acetyl-LGL)-β-CD provided by Seyedi et al. ; PC-12 cells purchased from Pasteur Institute, Tehran, Iran; Dulbecco’s Modified Eagle’s Medium (DMEM) 4.5 mg/ml glucose, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylterazolium bromide (MTT), penicillin, and streptomycin from Gibco, USA; L-glutamine, fetal bovine serum (FBS), trypsin, and dimethyl sulfoxide (DMSO) from Merck, Germany; low and normal-melting temperature agarose (LMA and NMA, respectively) from Biogen, USA; ethidium bromide (EB), thiobarbituric acid (TBA), hydrochloric acid (HCl), trichloroacetic acid (TCA), Bicinchoninic Acid (BCA) Kit, sodium chloride (NaCl), ethylenediaminetetracetic acid disodium salt (Na2EDTA), tris-(hydroxymethyl)-aminomethane (Tris–HCl), sodium N-lauroyl-sarcosinate, Triton X-100, and sodium hydroxide (NaOH) from Sigma-Aldrich, Germany.
PC-12 cells were cultured with DMEM (high glucose, 4.5 mg/ml glucose) which was supplemented with 10% FBS, 2 mM of L-glutamine, 100 U/ml of penicillin and 100 μg/ml of streptomycin and maintained in a humanized atmosphere (90%) containing 5% CO2 at 37°C. ATCC instructions were used to perform subculture. Throughout the experiment, after 2–3 days at 80-90% confluency, cells were plated on sterile poly-L-lysine coated 96-well microplates (5000 cells/well) and were used 24 h later.
Cell survival assay
After 24 h seeding, cells were treated with different concentrations (50, 200, 400, and 800 μg/ml) of hepta-(N-acetyl-LGL)-β-CD and incubated for 6, 12, and 24 h. MTT assay was used to determine cell viability . Briefly, MTT (5 mg/ml) was added to each well and cells were cultured for 3 h at 37°C to allow the reaction to proceed. Then, the media was removed and the reduced formazan crystals were dissolved in 100 μl DMSO. The absorbance of each well was read at 550 nm using a microplate reader (VICTOR™ X3 Multilabel Plate Reader, Perkin Elmer, Finland). For each concentration three wells were prepared and each plate was run in triplicate.
Alkaline single cell gel electrophoresis or comet assay
Comet assay was performed as a three-layer procedure under alkaline (pH > 13) conditions  with some modifications. For a typical experiment, cells were seeded in sterile poly-L-lysine coated 12-well plates (106 cells/well) and incubated at 37°C in 90% humanized atmosphere, 5% CO2 for 24 h. The cultured cells were then washed with PBS and exposed to different concentrations of hepta-(N-acetyl-LGL)-β-CD (50, 200 and 800 μg/ml) for 6, 12, and 24 h. After that, cells were trypsinized, centrifuged at 3000 g for 4 min. 50 μl of cell pellet was suspended in 300 μl LMP agarose 1%, which was dissolved in PBS, and kept at 37°C in water bath. 150 μl of cell/agarose mixture was spread on a conventional 26 mm × 76 mm microscope slides precoated with 100 μl of NMP agarose 1% and covered with a top layer of NMP agarose 1%. Before the LMP agarose solidified, a cover slip was added. Subsequently, the embedded cells were placed in a lysis solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris–HCl, 1% sodium N-lauroyl-sarcosinate, 1% Triton X-100, and 10% DMSO; pH 10) for 24 h at 4°C. The following day, the slides were placed in a horizontal electrophoresis tank, immersed and left in fresh cold alkaline electrophoresis buffer solution (300 mM NaOH, 1 mM Na2EDTA; pH > 13) for 40 min at 4°C. Electrophoresis was performed using the same solution for 40 min by applying an electric field of 24 V and adjusting the current to 300 mA. Finally, the slides were washed three times with neutralization buffer (400 mM Tris–HCl buffer; pH 7.5). After washing with deionized water, the slides were placed at room temperature for 48 h to dry and then stained with 50 μl of EB (20 μg/ml). Three wells were treated for each experimental group and each experiment was repeated three times.
Evaluation of DNA damage
Fluorescence microscope (Eclipse TE2000, Nikon, Japan) applying 520–550 nm excitation filter and 580 nm barrier filter was used to visualize EB stained slides (magnification 400×). Comet assay software project (CASP) was applied to determine percentage of tail DNA of each nucleoid. One hundred nucleoids for each concentration (50 per slide) were analyzed for quantification of DNA damage.
Measurement of malondialdehyde (MDA)
PC-12 cells were cultured in sterile poly-L-lysine coated 12- well plates (106 cells/well) according to the procedures described above and exposed to the sample solutions (50, 200, and 800 μg/ml). The malondialdehyde (MDA) content, as a measure of lipid peroxidation, was assayed using the protocol described by Mihara et al. with some modifications . After treatment for 6, 12, and 24 h, the cells were homogenized. Next, 2 mL of 0.7% TBA, 0.25 M HCl, and 15% TCA mixture was added to the homogenate, vortexed well and incubated in boiling water for 20 min following by centrifugation at 3000 g for 5 min at 4°C. The absorbance of the resulting supernatants was then immediately measured for the levels of MDA at 530 and 550 excitation and emission wavelength, respectively. Finally, the total protein content of the samples was determined by BCA Kit to normalize the levels of MDA. MDA levels were expressed in nmol/mg protein.
All data are expressed as mean ± SEM. One Way Analysis of Variance (ANOVA) followed by Tukey or Bonferroni’s post-hoc test using GraphPad InStat version 3.00 (GraphPad Software, San Diego, California, USA) was used to perform statistical analysis. P value less than 0.05 was considered to be statistically significant.
Evaluation of DNA damage by comet assay
Effects of hepta-(N-acetyl-LGL)-β-CD on MDA
In conclusion, we revealed that new β-CD derivative, hepta-(N-acetyl-LGL)-β-CD, is a potential cytotoxic agent. The results showed that measurement of lipid peroxidation and DNA damage contents may be simple markers to evaluate the cytotoxicity of novel β-CD derivatives and provide information for future studies to find a safer peptide substitution or to alter the peptide structure. However, potential safety hazards of this carrier in pharmaceutical formulations need further in vivo studies.
The authors are thankful to the Vice Chancellor of Research, Mashhad University of Medical Sciences for financial support. The results described in this paper are part of a Pharm.D thesis.
- Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A, Loftsson T: Cyclodextrin-based nanogels for pharmaceutical and biomedical applications. Int J Pharm. 2012, 428: 152-163. 10.1016/j.ijpharm.2012.02.038.View ArticlePubMedGoogle Scholar
- Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol. 2011, 63: 1119-1135. 10.1111/j.2042-7158.2011.01279.x.View ArticlePubMedGoogle Scholar
- Albers E, Muller BW: Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst. 1995, 12: 311-337. 10.1615/CritRevTherDrugCarrierSyst.v12.i4.20.View ArticlePubMedGoogle Scholar
- Davis ME, Brewster ME: Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004, 3: 1023-1035. 10.1038/nrd1576.View ArticlePubMedGoogle Scholar
- Szejtli J: Medicinal applications of cyclodextrins. Med Res Rev. 1994, 14: 353-386. 10.1002/med.2610140304.View ArticlePubMedGoogle Scholar
- Uekama K, Otagiri M: Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst. 1987, 3: 1-40.PubMedGoogle Scholar
- Loftsson T, Hreinsdottir D, Stefansson E: Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol. 2007, 59: 629-635. 10.1211/jpp.59.5.0002.View ArticlePubMedGoogle Scholar
- Gould S, Scott RC: 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005, 43: 1451-1459. 10.1016/j.fct.2005.03.007.View ArticlePubMedGoogle Scholar
- Stella VJ, He Q: Cyclodextrins. Toxicol Pathol. 2008, 36: 30-42. 10.1177/0192623307310945.View ArticlePubMedGoogle Scholar
- Irie T, Uekama K: Pharmaceutical applications of cyclodextrins.3. Toxicological issues and safety evaluation. J Pharm Sci. 1997, 86: 147-162. 10.1021/js960213f.View ArticlePubMedGoogle Scholar
- Leroylechat F, Wouessidjewe D, Andreux JP, Puisieux F, Duchene D: Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int J Pharm. 1994, 101: 97-103. 10.1016/0378-5173(94)90080-9.View ArticleGoogle Scholar
- Thompson DO: Cyclodextrins - enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 1997, 14: 1-104.View ArticlePubMedGoogle Scholar
- Seyedi SM, Sadeghian H, Jabbari A, Assadi A, Momeni H: Design and synthesis of a new series of amphiphilic peptide-β-cyclodextrins as phase transfer carriers for glucosamine. Tetrahedron. 2010, 66: 6754-6760. 10.1016/j.tet.2010.06.075.View ArticleGoogle Scholar
- Mehri S, Abnous K, Mousavi SH, Shariaty VM, Hosseinzadeh H: Neuroprotective effect of crocin on acrylamide-induced cytotoxicity in PC12 cells. Cell Mol Neurobiol. 2012, 32: 227-235. 10.1007/s10571-011-9752-8.View ArticlePubMedGoogle Scholar
- Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988, 175: 184-191. 10.1016/0014-4827(88)90265-0.View ArticlePubMedGoogle Scholar
- Mihara M, Uchiyama M: Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978, 86: 271-278. 10.1016/0003-2697(78)90342-1.View ArticlePubMedGoogle Scholar
- Moller P: Genotoxicity of environmental agents assessed by the alkaline comet assay. Basic Clin Pharmacol Toxicol. 2005, 96 (Suppl 1): 1-42.PubMedGoogle Scholar
- Janero DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990, 9: 515-540. 10.1016/0891-5849(90)90131-2.View ArticlePubMedGoogle Scholar
- Kiss T, Fenyvesi F, Bacskay I, Varadi J, Fenyvesi E, Ivanyi R, Szente L, Tosaki A, Vecsernyes M: Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur J Pharm Sci. 2010, 40: 376-380. 10.1016/j.ejps.2010.04.014.View ArticlePubMedGoogle Scholar
- Pourmand A, Abdollahi M: Current opinion on nanotoxicology. Daru. 2012, 20: 95-10.1186/2008-2231-20-95.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.